nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—SLCO1A2—Chlorambucil—testicular cancer	0.155	0.204	CbGbCtD
Naproxen—AKR1C3—Doxorubicin—testicular cancer	0.144	0.19	CbGbCtD
Naproxen—UGT2B7—Epirubicin—testicular cancer	0.0848	0.112	CbGbCtD
Naproxen—PTGS1—Ifosfamide—testicular cancer	0.0607	0.0799	CbGbCtD
Naproxen—UGT1A1—Etoposide—testicular cancer	0.0571	0.0752	CbGbCtD
Naproxen—CYP2C8—Ifosfamide—testicular cancer	0.035	0.0461	CbGbCtD
Naproxen—PTGS2—Cisplatin—testicular cancer	0.035	0.046	CbGbCtD
Naproxen—PTGS2—Etoposide—testicular cancer	0.0343	0.0452	CbGbCtD
Naproxen—PTGS1—Etoposide—testicular cancer	0.029	0.0382	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—testicular cancer	0.0277	0.0365	CbGbCtD
Naproxen—CYP2C9—Ifosfamide—testicular cancer	0.0244	0.0322	CbGbCtD
Naproxen—SLC22A6—Methotrexate—testicular cancer	0.0168	0.0221	CbGbCtD
Naproxen—CYP2C8—Etoposide—testicular cancer	0.0167	0.022	CbGbCtD
Naproxen—ALB—Methotrexate—testicular cancer	0.0143	0.0188	CbGbCtD
Naproxen—CYP1A2—Etoposide—testicular cancer	0.013	0.0171	CbGbCtD
Naproxen—CYP2C9—Cisplatin—testicular cancer	0.0119	0.0156	CbGbCtD
Naproxen—AKR1C3—Podofilox—Etoposide—testicular cancer	0.00256	0.539	CbGdCrCtD
Naproxen—AKR1C3—Vincristine—Vinblastine—testicular cancer	0.00219	0.461	CbGdCrCtD
Naproxen—Abdominal pain—Etoposide—testicular cancer	9.57e-05	0.000406	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—testicular cancer	9.56e-05	0.000406	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—testicular cancer	9.56e-05	0.000406	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—testicular cancer	9.55e-05	0.000405	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—testicular cancer	9.55e-05	0.000405	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—testicular cancer	9.53e-05	0.000405	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—testicular cancer	9.51e-05	0.000404	CcSEcCtD
Naproxen—Asthenia—Cisplatin—testicular cancer	9.48e-05	0.000402	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—testicular cancer	9.48e-05	0.000402	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—testicular cancer	9.47e-05	0.000402	CcSEcCtD
Naproxen—Sweating—Doxorubicin—testicular cancer	9.43e-05	0.0004	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—testicular cancer	9.43e-05	0.0004	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—testicular cancer	9.4e-05	0.000399	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—testicular cancer	9.38e-05	0.000398	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—testicular cancer	9.38e-05	0.000398	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—testicular cancer	9.36e-05	0.000397	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—testicular cancer	9.31e-05	0.000395	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—testicular cancer	9.28e-05	0.000394	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—testicular cancer	9.26e-05	0.000393	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—testicular cancer	9.23e-05	0.000392	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—testicular cancer	9.21e-05	0.000391	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—testicular cancer	9.2e-05	0.000391	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—testicular cancer	9.19e-05	0.00039	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—testicular cancer	9.18e-05	0.00039	CcSEcCtD
Naproxen—Chills—Methotrexate—testicular cancer	9.15e-05	0.000389	CcSEcCtD
Naproxen—Nausea—Ifosfamide—testicular cancer	9.1e-05	0.000386	CcSEcCtD
Naproxen—Diarrhoea—Cisplatin—testicular cancer	9.04e-05	0.000384	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—testicular cancer	9.03e-05	0.000383	CcSEcCtD
Naproxen—Alopecia—Methotrexate—testicular cancer	9.01e-05	0.000383	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—testicular cancer	8.94e-05	0.000379	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—testicular cancer	8.92e-05	0.000379	CcSEcCtD
Naproxen—Hypersensitivity—Etoposide—testicular cancer	8.91e-05	0.000378	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—testicular cancer	8.9e-05	0.000378	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—testicular cancer	8.88e-05	0.000377	CcSEcCtD
Naproxen—Erythema—Methotrexate—testicular cancer	8.88e-05	0.000377	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—testicular cancer	8.88e-05	0.000377	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—testicular cancer	8.86e-05	0.000376	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—testicular cancer	8.86e-05	0.000376	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—testicular cancer	8.83e-05	0.000375	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—testicular cancer	8.83e-05	0.000375	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—testicular cancer	8.77e-05	0.000372	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—testicular cancer	8.72e-05	0.00037	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—testicular cancer	8.7e-05	0.000369	CcSEcCtD
Naproxen—Asthenia—Etoposide—testicular cancer	8.68e-05	0.000369	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—testicular cancer	8.68e-05	0.000369	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—testicular cancer	8.66e-05	0.000368	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—testicular cancer	8.66e-05	0.000368	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—testicular cancer	8.62e-05	0.000366	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—testicular cancer	8.6e-05	0.000365	CcSEcCtD
Naproxen—Chills—Epirubicin—testicular cancer	8.57e-05	0.000364	CcSEcCtD
Naproxen—Pruritus—Etoposide—testicular cancer	8.56e-05	0.000363	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—testicular cancer	8.53e-05	0.000362	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—testicular cancer	8.51e-05	0.000361	CcSEcCtD
Naproxen—Alopecia—Epirubicin—testicular cancer	8.44e-05	0.000358	CcSEcCtD
Naproxen—Vomiting—Cisplatin—testicular cancer	8.4e-05	0.000357	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—testicular cancer	8.37e-05	0.000355	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—testicular cancer	8.36e-05	0.000355	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—testicular cancer	8.35e-05	0.000355	CcSEcCtD
Naproxen—Rash—Cisplatin—testicular cancer	8.33e-05	0.000354	CcSEcCtD
Naproxen—Dermatitis—Cisplatin—testicular cancer	8.32e-05	0.000353	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—testicular cancer	8.31e-05	0.000353	CcSEcCtD
Naproxen—Erythema—Epirubicin—testicular cancer	8.31e-05	0.000353	CcSEcCtD
Naproxen—Diarrhoea—Etoposide—testicular cancer	8.28e-05	0.000351	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—testicular cancer	8.26e-05	0.00035	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—testicular cancer	8.24e-05	0.00035	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—testicular cancer	8.24e-05	0.00035	CcSEcCtD
Naproxen—Anaemia—Methotrexate—testicular cancer	8.21e-05	0.000348	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—testicular cancer	8.2e-05	0.000348	CcSEcCtD
Naproxen—Flatulence—Epirubicin—testicular cancer	8.19e-05	0.000348	CcSEcCtD
Naproxen—Tension—Epirubicin—testicular cancer	8.16e-05	0.000346	CcSEcCtD
Naproxen—Nervousness—Epirubicin—testicular cancer	8.07e-05	0.000343	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—testicular cancer	8.01e-05	0.00034	CcSEcCtD
Naproxen—Malaise—Methotrexate—testicular cancer	8.01e-05	0.00034	CcSEcCtD
Naproxen—Dizziness—Etoposide—testicular cancer	8e-05	0.00034	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—testicular cancer	7.99e-05	0.000339	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—testicular cancer	7.98e-05	0.000339	CcSEcCtD
Naproxen—Vertigo—Methotrexate—testicular cancer	7.98e-05	0.000339	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—testicular cancer	7.96e-05	0.000338	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—testicular cancer	7.95e-05	0.000337	CcSEcCtD
Naproxen—Chills—Doxorubicin—testicular cancer	7.93e-05	0.000336	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—testicular cancer	7.89e-05	0.000335	CcSEcCtD
Naproxen—Nausea—Cisplatin—testicular cancer	7.85e-05	0.000333	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—testicular cancer	7.83e-05	0.000333	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—testicular cancer	7.81e-05	0.000331	CcSEcCtD
Naproxen—Cough—Methotrexate—testicular cancer	7.75e-05	0.000329	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—testicular cancer	7.74e-05	0.000329	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—testicular cancer	7.71e-05	0.000327	CcSEcCtD
Naproxen—Convulsion—Methotrexate—testicular cancer	7.69e-05	0.000327	CcSEcCtD
Naproxen—Vomiting—Etoposide—testicular cancer	7.69e-05	0.000327	CcSEcCtD
Naproxen—Erythema—Doxorubicin—testicular cancer	7.69e-05	0.000326	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—testicular cancer	7.69e-05	0.000326	CcSEcCtD
Naproxen—Anaemia—Epirubicin—testicular cancer	7.68e-05	0.000326	CcSEcCtD
Naproxen—Rash—Etoposide—testicular cancer	7.63e-05	0.000324	CcSEcCtD
Naproxen—Dermatitis—Etoposide—testicular cancer	7.62e-05	0.000324	CcSEcCtD
Naproxen—Headache—Etoposide—testicular cancer	7.58e-05	0.000322	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—testicular cancer	7.58e-05	0.000322	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—testicular cancer	7.56e-05	0.000321	CcSEcCtD
Naproxen—Chest pain—Methotrexate—testicular cancer	7.56e-05	0.000321	CcSEcCtD
Naproxen—Myalgia—Methotrexate—testicular cancer	7.56e-05	0.000321	CcSEcCtD
Naproxen—Tension—Doxorubicin—testicular cancer	7.55e-05	0.00032	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	7.51e-05	0.000319	CcSEcCtD
Naproxen—Malaise—Epirubicin—testicular cancer	7.49e-05	0.000318	CcSEcCtD
Naproxen—Discomfort—Methotrexate—testicular cancer	7.47e-05	0.000317	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—testicular cancer	7.47e-05	0.000317	CcSEcCtD
Naproxen—Vertigo—Epirubicin—testicular cancer	7.47e-05	0.000317	CcSEcCtD
Naproxen—Syncope—Epirubicin—testicular cancer	7.45e-05	0.000316	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—testicular cancer	7.44e-05	0.000316	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—testicular cancer	7.39e-05	0.000314	CcSEcCtD
Naproxen—Palpitations—Epirubicin—testicular cancer	7.34e-05	0.000312	CcSEcCtD
Naproxen—Confusional state—Methotrexate—testicular cancer	7.31e-05	0.00031	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—testicular cancer	7.3e-05	0.00031	CcSEcCtD
Naproxen—Cough—Epirubicin—testicular cancer	7.25e-05	0.000308	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—testicular cancer	7.25e-05	0.000308	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—testicular cancer	7.25e-05	0.000308	CcSEcCtD
Naproxen—Convulsion—Epirubicin—testicular cancer	7.2e-05	0.000306	CcSEcCtD
Naproxen—Infection—Methotrexate—testicular cancer	7.2e-05	0.000306	CcSEcCtD
Naproxen—Nausea—Etoposide—testicular cancer	7.19e-05	0.000305	CcSEcCtD
Naproxen—Hypertension—Epirubicin—testicular cancer	7.18e-05	0.000305	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—testicular cancer	7.13e-05	0.000303	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—testicular cancer	7.11e-05	0.000302	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—testicular cancer	7.11e-05	0.000302	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—testicular cancer	7.1e-05	0.000301	CcSEcCtD
Naproxen—Chest pain—Epirubicin—testicular cancer	7.08e-05	0.0003	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—testicular cancer	7.08e-05	0.0003	CcSEcCtD
Naproxen—Myalgia—Epirubicin—testicular cancer	7.08e-05	0.0003	CcSEcCtD
Naproxen—Anxiety—Epirubicin—testicular cancer	7.05e-05	0.000299	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—testicular cancer	7.04e-05	0.000299	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	7.03e-05	0.000298	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—testicular cancer	7.01e-05	0.000297	CcSEcCtD
Naproxen—Discomfort—Epirubicin—testicular cancer	6.99e-05	0.000297	CcSEcCtD
Naproxen—Malaise—Doxorubicin—testicular cancer	6.93e-05	0.000294	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—testicular cancer	6.92e-05	0.000294	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—testicular cancer	6.91e-05	0.000293	CcSEcCtD
Naproxen—Anorexia—Methotrexate—testicular cancer	6.91e-05	0.000293	CcSEcCtD
Naproxen—Syncope—Doxorubicin—testicular cancer	6.9e-05	0.000293	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—testicular cancer	6.88e-05	0.000292	CcSEcCtD
Naproxen—Confusional state—Epirubicin—testicular cancer	6.84e-05	0.00029	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—testicular cancer	6.8e-05	0.000288	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—testicular cancer	6.78e-05	0.000288	CcSEcCtD
Naproxen—Oedema—Epirubicin—testicular cancer	6.78e-05	0.000288	CcSEcCtD
Naproxen—Hypotension—Methotrexate—testicular cancer	6.77e-05	0.000288	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—testicular cancer	6.76e-05	0.000287	CcSEcCtD
Naproxen—Infection—Epirubicin—testicular cancer	6.74e-05	0.000286	CcSEcCtD
Naproxen—Cough—Doxorubicin—testicular cancer	6.71e-05	0.000285	CcSEcCtD
Naproxen—Shock—Epirubicin—testicular cancer	6.67e-05	0.000283	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—testicular cancer	6.66e-05	0.000283	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—testicular cancer	6.65e-05	0.000282	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—testicular cancer	6.64e-05	0.000282	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—testicular cancer	6.64e-05	0.000282	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—testicular cancer	6.62e-05	0.000281	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.6e-05	0.00028	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—testicular cancer	6.59e-05	0.00028	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—testicular cancer	6.56e-05	0.000278	CcSEcCtD
Naproxen—Insomnia—Methotrexate—testicular cancer	6.56e-05	0.000278	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—testicular cancer	6.55e-05	0.000278	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—testicular cancer	6.55e-05	0.000278	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—testicular cancer	6.55e-05	0.000278	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—testicular cancer	6.52e-05	0.000277	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—testicular cancer	6.51e-05	0.000276	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	6.5e-05	0.000276	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—testicular cancer	6.47e-05	0.000275	CcSEcCtD
Naproxen—Anorexia—Epirubicin—testicular cancer	6.47e-05	0.000274	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—testicular cancer	6.46e-05	0.000274	CcSEcCtD
Naproxen—Somnolence—Methotrexate—testicular cancer	6.44e-05	0.000274	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—testicular cancer	6.4e-05	0.000272	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—testicular cancer	6.38e-05	0.000271	CcSEcCtD
Naproxen—Hypotension—Epirubicin—testicular cancer	6.34e-05	0.000269	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—testicular cancer	6.33e-05	0.000269	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—testicular cancer	6.3e-05	0.000267	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—testicular cancer	6.28e-05	0.000266	CcSEcCtD
Naproxen—Oedema—Doxorubicin—testicular cancer	6.28e-05	0.000266	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—testicular cancer	6.26e-05	0.000266	CcSEcCtD
Naproxen—Fatigue—Methotrexate—testicular cancer	6.25e-05	0.000265	CcSEcCtD
Naproxen—Infection—Doxorubicin—testicular cancer	6.23e-05	0.000265	CcSEcCtD
Naproxen—Pain—Methotrexate—testicular cancer	6.2e-05	0.000263	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.18e-05	0.000262	CcSEcCtD
Naproxen—Shock—Doxorubicin—testicular cancer	6.17e-05	0.000262	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—testicular cancer	6.15e-05	0.000261	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—testicular cancer	6.14e-05	0.000261	CcSEcCtD
Naproxen—Insomnia—Epirubicin—testicular cancer	6.13e-05	0.00026	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—testicular cancer	6.13e-05	0.00026	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—testicular cancer	6.1e-05	0.000259	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—testicular cancer	6.09e-05	0.000259	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—testicular cancer	6.07e-05	0.000258	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—testicular cancer	6.05e-05	0.000257	CcSEcCtD
Naproxen—Somnolence—Epirubicin—testicular cancer	6.03e-05	0.000256	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—testicular cancer	5.98e-05	0.000254	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—testicular cancer	5.97e-05	0.000254	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—testicular cancer	5.97e-05	0.000253	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—testicular cancer	5.93e-05	0.000252	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—testicular cancer	5.9e-05	0.00025	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—testicular cancer	5.86e-05	0.000249	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—testicular cancer	5.86e-05	0.000249	CcSEcCtD
Naproxen—Fatigue—Epirubicin—testicular cancer	5.85e-05	0.000248	CcSEcCtD
Naproxen—Pain—Epirubicin—testicular cancer	5.8e-05	0.000246	CcSEcCtD
Naproxen—Constipation—Epirubicin—testicular cancer	5.8e-05	0.000246	CcSEcCtD
Naproxen—Urticaria—Methotrexate—testicular cancer	5.76e-05	0.000244	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—testicular cancer	5.73e-05	0.000243	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—testicular cancer	5.73e-05	0.000243	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.72e-05	0.000243	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—testicular cancer	5.68e-05	0.000241	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—testicular cancer	5.64e-05	0.000239	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—testicular cancer	5.6e-05	0.000238	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—testicular cancer	5.59e-05	0.000237	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—testicular cancer	5.58e-05	0.000237	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—testicular cancer	5.55e-05	0.000235	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—testicular cancer	5.52e-05	0.000235	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—testicular cancer	5.46e-05	0.000232	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.42e-05	0.00023	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—testicular cancer	5.41e-05	0.00023	CcSEcCtD
Naproxen—Urticaria—Epirubicin—testicular cancer	5.39e-05	0.000229	CcSEcCtD
Naproxen—Pain—Doxorubicin—testicular cancer	5.37e-05	0.000228	CcSEcCtD
Naproxen—Constipation—Doxorubicin—testicular cancer	5.37e-05	0.000228	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—testicular cancer	5.36e-05	0.000228	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—testicular cancer	5.36e-05	0.000228	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—testicular cancer	5.34e-05	0.000227	CcSEcCtD
Naproxen—Asthenia—Methotrexate—testicular cancer	5.2e-05	0.000221	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—testicular cancer	5.17e-05	0.00022	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—testicular cancer	5.13e-05	0.000218	CcSEcCtD
Naproxen—Pruritus—Methotrexate—testicular cancer	5.13e-05	0.000218	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—testicular cancer	5e-05	0.000212	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—testicular cancer	4.99e-05	0.000212	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—testicular cancer	4.96e-05	0.000211	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—testicular cancer	4.96e-05	0.000211	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—testicular cancer	4.96e-05	0.000211	CcSEcCtD
Naproxen—Asthenia—Epirubicin—testicular cancer	4.87e-05	0.000207	CcSEcCtD
Naproxen—Pruritus—Epirubicin—testicular cancer	4.8e-05	0.000204	CcSEcCtD
Naproxen—Dizziness—Methotrexate—testicular cancer	4.79e-05	0.000203	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—testicular cancer	4.64e-05	0.000197	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—testicular cancer	4.62e-05	0.000196	CcSEcCtD
Naproxen—Vomiting—Methotrexate—testicular cancer	4.61e-05	0.000196	CcSEcCtD
Naproxen—Rash—Methotrexate—testicular cancer	4.57e-05	0.000194	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—testicular cancer	4.57e-05	0.000194	CcSEcCtD
Naproxen—Headache—Methotrexate—testicular cancer	4.54e-05	0.000193	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—testicular cancer	4.5e-05	0.000191	CcSEcCtD
Naproxen—Dizziness—Epirubicin—testicular cancer	4.49e-05	0.00019	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—testicular cancer	4.44e-05	0.000188	CcSEcCtD
Naproxen—Vomiting—Epirubicin—testicular cancer	4.31e-05	0.000183	CcSEcCtD
Naproxen—Nausea—Methotrexate—testicular cancer	4.31e-05	0.000183	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—testicular cancer	4.29e-05	0.000182	CcSEcCtD
Naproxen—Rash—Epirubicin—testicular cancer	4.28e-05	0.000182	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—testicular cancer	4.27e-05	0.000181	CcSEcCtD
Naproxen—Headache—Epirubicin—testicular cancer	4.25e-05	0.00018	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—testicular cancer	4.15e-05	0.000176	CcSEcCtD
Naproxen—Nausea—Epirubicin—testicular cancer	4.03e-05	0.000171	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—testicular cancer	3.99e-05	0.000169	CcSEcCtD
Naproxen—Rash—Doxorubicin—testicular cancer	3.96e-05	0.000168	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—testicular cancer	3.95e-05	0.000168	CcSEcCtD
Naproxen—Headache—Doxorubicin—testicular cancer	3.93e-05	0.000167	CcSEcCtD
Naproxen—Nausea—Doxorubicin—testicular cancer	3.73e-05	0.000158	CcSEcCtD
